Investor Relations

Investor FAQs

 

Answer: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair in the United States, Europe, and internationally. The Company is a leader in the viscosupplemention market with activities in multiple additional markets, including orthopedic and regenerative medicine, dermal products, surgical products, ophthalmic products and veterinary products. Anika's products are based on hyaluronic acid (HA) technology, a naturally occurring, biocompatible polymer found throughout the body, which acts to enhance joint function, to coat, protect, cushion and lubricate soft tissues, and to support skin structure and elasticity.

Anika was founded in 1992.

Anika is traded on the Nasdaq Global Select Market under the symbol ANIK.

Anika’s fiscal year ends December 31.

With 20 years of experience in its field, Anika has many competitive strengths including:

- Unique expertise in efficiently manufacturing extremely pure, high molecular weight HA-based products with exceptional safety profiles in state-of-the-art manufacturing facility located at the company's headquarters.

- Viscosupplementation products contain highest concentration of non-animal sourced HA among competitors providing for maximum effectiveness at lower injectable volumes.

- Strong product pipeline will continue to allow the company to deliver new and improved products to the market.

- Strong brand recognition as a result of robust distribution network.

Please visit Anika’s Information Request page to receive an investor kit.

Please click here for more information.

Anika’s financial statements are available for viewing in the SEC Filings section of its investor relations website. To receive a hard copy of the Company’s financial statements, please visit the Information Request section of the site and complete the electronic form provided.

For detailed information about Anika’s management team, click here.

For detailed information about Anika’s Board of Directors, click here.

Anika has never declared a cash dividend on its common stock, nor does it presently have any plans to initiate a dividend program.

Anika does not have a direct stock purchase program, and presently does not anticipate establishing one.

For detailed Contact information, please click here.

PricewaterhouseCoopers LLP is Anika’s accounting firm.

K&L Gates LLP serves as the Company’s outside general legal counsel.

Anika’s CUSIP number is 035255 10 8.

Please contact:
Sylvia Cheung
Chief Financial Officer
781-457-9000
investorrelations@anikatherapeutics.com

Please submit your question using the form below.

* Indicates required field